Madeleine Duvic

Madeleine Duvic played a central role in the clinical development and FDA approval of bexarotene (Targretin) for CTCL, demonstrating responses across stages in pivotal phase II and III trials. Over a decades-long career, she established MD Anderson's CTCL program as a world reference center and contributed seminal work on topical, phototherapy, and systemic approaches for cutaneous lymphoma. She is a past president of ISCL and has trained generations of CTCL specialists.